

Treatment Naïve, Chronic HCV

Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3

Mangia A, et al. N Engl J Med. 2005;352:1609-17.


Peginterferon alfa-2b + RBV for 12 or 24 Weeks in GT 2 or 3

Study Design

- **Study**
 - Randomized, open-label trial
 - Conducted in 12 centers in Italy
- **Subjects**
 - N = 283 with chronic hepatitis C
 - Treatment naïve adult patients
 - Genotype 2 or 3
- **Regimens**
 - Peginterferon alfa-2b: 1.0 µg/kg/wk + Ribavirin: 1000-1200 mg/d x 24 wks
 - Peginterferon alfa-2b: 1.0 µg/kg/wk + Ribavirin: 1000-1200 mg/d x 12 or 24 wks*
- **Primary Endpoint**
 - Undetectable serum HCV RNA at end of treatment (ETR)
 - Undetectable serum HCV RNA 24 wks after cessation of treatment (SVR)

*Duration based on whether week 4 HCV RNA negative (12 weeks) or positive (24 weeks)

Peginterferon alfa-2b + RBV for 12 or 24 Weeks in GT 2 or 3 Treatment Duration and Ribavirin Dose



Drug Dosing


Peginterferon alfa-2b: 1.5 µg/kg 1x/week

Ribavirin (divided bid): <75 kg (1000 mg/day); ≥75 kg (1200 mg/day)

Peginterferon alfa-2b + RBV for 12 or 24 Weeks in GT 2 or 3

Treatment Duration and Ribavirin Dose

SVR24 Rates, by Regimen



Peginterferon alfa-2b + RBV for 12 or 24 Weeks in GT 2 or 3

Conclusions

Conclusions: “A shorter course of therapy over 12 weeks with peginterferon alfa-2b and ribavirin is as effective as a 24-week course for patients with HCV genotype 2 or 3 who have a response to treatment at 4 weeks.”

This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online
www.hepatitisc.uw.edu

Hepatitis Web Study
<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.